Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections
Journal of Antimicrobial Chemotherapy · 03.05.2023 · 78 (5) · 1195-1200
DOI: 10.1093/jac/dkad062 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 15.03.2023. Verfasst von Isaac Alonso-García und 17 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, Ciber de Enfermed…. Hauptthemen laut MEDLINE: Ceftazidime, Pseudomonas Infections. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, ISCIII.
Abstract (Originalsprache)
Objectives
To describe and characterize the emergence of resistance to ceftolozane/tazobactam, ceftazidime/avibactam and imipenem/relebactam in a patient receiving ceftazidime/avibactam treatment for an MDR Pseudomonas aeruginosa CNS infection.
Methods
One baseline (PA1) and two post-exposure (PA2 and PA3) isolates obtained before and during treatment of a nosocomial P. aeruginosa meningoventriculitis were evaluated. MICs were determined by broth microdilution. Mutational changes were investigated through WGS. The impact on β-lactam resistance of mutations in blaPDC and mexR was determined through cloning experiments and complementation assays.
Results
Isolate PA1 showed baseline resistance mutations in DacB (I354A) and OprD (N142fs) conferring resistance to conventional antipseudomonals but susceptibility to ceftazidime/avibactam, ceftolozane/tazobactam and imipenem/relebactam. Post-exposure isolates showed two divergent ceftazidime/avibactam-resistant phenotypes associated with distinctive mutations affecting the intrinsic P PDC β-lactamase (S254Ins) (PA2: ceftolozane/tazobactam and ceftazidime/avibactam-resistant) or MexAB-OprM negative regulator MexR in combination with modification of PBP3 (PA3: ceftazidime/avibactam and imipenem/relebactam-relebactam-resistant). Cloning experiments demonstrated the role of PDC modification in resistance to ceftolozane/tazobactam and ceftazidime/avibactam. Complementation with a functional copy of the mexR gene in isolate PA3 restored imipenem/relebactam susceptibility.
Conclusions
We demonstrated how P. aeruginosa may simultaneously develop resistance and compromise the activity of new β-lactam/β-lactamase inhibitor combinations when exposed to ceftazidime/avibactam through selection of mutations leading to PDC modification and up-regulation of MexAB-OprM-mediated efflux.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Servicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, Ciber de Enfermedades Infecciosas CIBERINFEC, A Coruña, Spain.
- Servicio de Microbiología and Instituto de Investigación e Innovación Biomédica de Cádiz (INiBICA), Hospital Universitario Puerta del Mar, Cádiz, Spain.
- Servicio de Microbiología and Unidad de Investigación, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Illes Balears (IdiSBA), Ciber de Enfermedades Infecciosas CIBERINFEC, Palma de Mallorca, Sp…
ORCID-Profile: Paula Guijarro-Sánchez, Alejandro Beceiro, Jorge Arca-Suárez, Fátima Galán-Sánchez
Förderung
- Fondo de Investigación Sanitaria
- Instituto de Salud Carlos III
- ISCIII
- Spanish Network of Research in Infectious Diseases
- European Regional Development Fund
- FEDER
- GAIN
Zitieren
APA
Alonso-García, I., Vázquez-Ucha, J. C., Lasarte-Monterrubio, C., González-Mayo, E., Lada-Salvador, P., Vela-Fernández, R., Aja-Macaya, P., Guijarro-Sánchez, P., Rumbo-Feal, S., Muíño-Andrade, M., Fernández-González, A., Martínez-Guitián, M., Beceiro, A., Rodríguez-Iglesias, M., Oliver, A., Arca-Suárez, J., Galán-Sánchez, F., & Bou, G. (2023). Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections. Journal of Antimicrobial Chemotherapy, 78(5), 1195-1200. https://doi.org/10.1093/jac/dkad062
Vancouver
Alonso-García I, Vázquez-Ucha JC, Lasarte-Monterrubio C, González-Mayo E, Lada-Salvador P, Vela-Fernández R, et al. Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections. Journal of Antimicrobial Chemotherapy. 2023;78(5):1195-1200. doi:10.1093/jac/dkad062
BibTeX
@article{AlonsoGarca2023,
author = {Alonso-García, Isaac and Vázquez-Ucha, Juan Carlos and Lasarte-Monterrubio, Cristina and González-Mayo, Elena and Lada-Salvador, Paula and Vela-Fernández, Ramón and Aja-Macaya, Pablo and Guijarro-Sánchez, Paula and Rumbo-Feal, Soraya and Muíño-Andrade, María and Fernández-González, Ana and Martínez-Guitián, Marta and Beceiro, Alejandro and Rodríguez-Iglesias, Manuel and Oliver, Antonio and Arca-Suárez, Jorge and Galán-Sánchez, Fátima and Bou, Germán},
title = {Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2023},
volume = {78},
number = {5},
pages = {1195--1200},
doi = {10.1093/jac/dkad062}
}
EUVIMED